Cargando…
Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210570/ https://www.ncbi.nlm.nih.gov/pubmed/30249978 http://dx.doi.org/10.3390/cancers10100350 |
_version_ | 1783367146016866304 |
---|---|
author | Rastrelli, Marco Ferrazzi, Beatrice Cavallin, Francesco Chiarion Sileni, Vanna Pigozzo, Jacopo Fabozzi, Alessio Tropea, Saveria Vecchiato, Antonella Costa, Alessandra Parisi, Alessandro Rossi, Carlo Riccardo Del Fiore, Paolo Alaibac, Mauro |
author_facet | Rastrelli, Marco Ferrazzi, Beatrice Cavallin, Francesco Chiarion Sileni, Vanna Pigozzo, Jacopo Fabozzi, Alessio Tropea, Saveria Vecchiato, Antonella Costa, Alessandra Parisi, Alessandro Rossi, Carlo Riccardo Del Fiore, Paolo Alaibac, Mauro |
author_sort | Rastrelli, Marco |
collection | PubMed |
description | Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04–8.16) and disease-specific (HR 4.62, 95% CI 1.31–16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06–4.36) and recurrence-free (HR 3.08, 95% CI 1.44–6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival. |
format | Online Article Text |
id | pubmed-6210570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62105702018-11-02 Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients Rastrelli, Marco Ferrazzi, Beatrice Cavallin, Francesco Chiarion Sileni, Vanna Pigozzo, Jacopo Fabozzi, Alessio Tropea, Saveria Vecchiato, Antonella Costa, Alessandra Parisi, Alessandro Rossi, Carlo Riccardo Del Fiore, Paolo Alaibac, Mauro Cancers (Basel) Article Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04–8.16) and disease-specific (HR 4.62, 95% CI 1.31–16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06–4.36) and recurrence-free (HR 3.08, 95% CI 1.44–6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival. MDPI 2018-09-24 /pmc/articles/PMC6210570/ /pubmed/30249978 http://dx.doi.org/10.3390/cancers10100350 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rastrelli, Marco Ferrazzi, Beatrice Cavallin, Francesco Chiarion Sileni, Vanna Pigozzo, Jacopo Fabozzi, Alessio Tropea, Saveria Vecchiato, Antonella Costa, Alessandra Parisi, Alessandro Rossi, Carlo Riccardo Del Fiore, Paolo Alaibac, Mauro Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients |
title | Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients |
title_full | Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients |
title_fullStr | Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients |
title_full_unstemmed | Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients |
title_short | Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients |
title_sort | prognostic factors in merkel cell carcinoma: a retrospective single-center study in 90 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210570/ https://www.ncbi.nlm.nih.gov/pubmed/30249978 http://dx.doi.org/10.3390/cancers10100350 |
work_keys_str_mv | AT rastrellimarco prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT ferrazzibeatrice prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT cavallinfrancesco prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT chiarionsilenivanna prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT pigozzojacopo prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT fabozzialessio prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT tropeasaveria prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT vecchiatoantonella prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT costaalessandra prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT parisialessandro prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT rossicarloriccardo prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT delfiorepaolo prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT alaibacmauro prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients |